Objectives: An effective HIV-1 vaccine must be able to block infection by a wide range of
viral isolates. PG9, PG16, PGT121, and PGT145 antibodies were identified from culture …

Objectives: HIV-1 initiates infection by fusing with CD4+ lymphocytes or macrophages,
mediated by the envelope protein Env (gp120/gp41). We developed a new HIV fusion assay …

Fusion of CD4+ cells by HIV-1 envelope proteins (Env) is a mechanism of virus spread and
cell damage. Production of antibodies able to influence cell–cell fusion in vivo may affect the …

Background: Broadly cross-reactive, neutralizing human monoclonal antibodies, including
2F5, 2G12, 4E10 and IgG1 b12, can inhibit HIV-1 infection in vitro at very low concentrations …

Results: Cell-cell fusion began 20-30 min after co-cultivation at 37 [degrees] C. Pre-binding
at 4 [degrees] C was observed not to decrease the lag phase before fusion. Cells expressing …

Methods: We used the HIV fusion assay developed previously in our laboratory.
Clone69TRevEnv cells (NIH AIDS Reagent Program) that express Env in the absence of …

HIV-1 infects host cells by fusion at the plasma membrane, mediated by the envelope
glycoprotein gp120/gp41 (Env). This process can be studied by monitoring syncytia …

Methods: We used the HIV fusion assay developed previously in our laboratory.
Clone69TRevEnv cells (NIH AIDS Reagent Program) that express Env in the absence of …

Human immunodeficiency virus type 1 (HIV-1) envelope glycoproteins present at the surface
of infected cells are known to mediate fusion with CD4-positive target cells. In this study we …

Interaction in vitro between cells infected with human immunodeficiency virus (HIV) and
surrounding, uninfected, target cells often leads to cell fusion and the formation of …